Neurocrine Biosciences Shares Rose Even As Profit Fell
Neurocrine Biosciences spent 2026 talking about concrete moves such as a US$2.9b cash deal for Soleno Therapeutics and fresh data readouts for CRENESSITY and VYKAT XR. Yet what really grabs attention is what simply holding the stock did for owners. Holding Neurocrine Biosciences from the start of the year would have returned 20.5%, including dividends. If you were deciding back on 1 January, what had to be true about future demand and pricing power to justify buying in?
This theme extends beyond Neurocrine Biosciences. See which of 35 healthcare AI stocks may still merit a closer look.
The Two Neurocrine Biosciences Stories Investors Were Pricing In
The shares cost US$142 at the start of the period, so anyone considering Neurocrine Biosciences then had to decide which future story felt more plausible.
On the positive side, one view saw a fair value of US$168, a rough estimate of where the price could land if that script played out, built on INGREZZA leadership, expanding payer access and a broad late stage CNS pipeline supporting higher earnings.
The cautious camp focused on a fair value of US$124, reflecting concerns that reliance on INGREZZA and CRENESSITY, tighter reimbursement and rising R&D costs might limit revenue growth and keep margins closer to 12.4%.
What The 2026 Evidence Tested For Neurocrine Biosciences
Neurocrine Biosciences delivered Q3 2026 revenue of US$1.12b, up from US$794.9m a year earlier, helped by INGREZZA, CRENESSITY and the completed Soleno deal that brought in VYKAT XR. That supported the optimistic demand story. Net income stayed roughly flat at about US$206.5m and net margin moved from 26.4% to 18.4%, which challenged the cleaner profitability leg of the bull case. Overall, the year’s evidence cut both ways.
The lesson is simple. When a thesis leans on both volume and pricing power, track revenue against net margin every quarter and check whether new products and acquisitions are widening or squeezing that margin over time.
What Today's Neurocrine Biosciences Price Already Assumes
Neurocrine Biosciences now trades at US$169 from the start of the year, with a 20.5% total return over that stretch. The analyst consensus Narrative on Simply Wall St places its Fair Value above the current level, based on a multi drug story rather than a single product bet.
That Narrative leans on INGREZZA, CRENESSITY, VYKAT XR and late stage psychiatry readouts, so a buyer today would need to judge whether future pipeline execution and obesity projects are still underappreciated.
"Expansion of Neurocrine Biosciences’ commercial portfolio beyond INGREZZA through the launch of CRENESSITY and the acquisition of VYKAT XR, which together supplied about 25% of Q2 2026 revenue off a roughly US$1b quarterly base, broadens revenue sources and can improve margin resilience as the company spreads infrastructure and R&D spending across three first in class endocrinology and neuropsychiatry franchises."
The price and this Narrative do not agree. → Uncover what this Narrative says Neurocrine Biosciences is actually worth
How Could You Get There Earlier?
What if your next investment idea came before the headlines? Go straight to the companies whose prices and our estimates still disagree. Three places to start, with the names waiting behind the link.
- Company 1 - 38% below our estimate - targets coffee demand through dense store rollout, app ordering, and frequent menu experiments.
- Company 2 - 44% below our estimate - shifts capital from a divested label into higher margin outdoor apparel and shareholder payouts.
- Company 3 - 46% below our estimate - builds digital tools that pull small business deposits and loans into a single primary relationship.
Those are three of them. See all 32 potentially undervalued companies →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com